Analysis of localization of adult T-cell leukemia-derived factor in the transient ischemic rat retina after treatment with OP-1206 alpha-CD, a prostaglandin E1 analogue.
Prostaglandin E1 (PGE1) is commonly used in therapy for obstructive diseases, including ischemic retinopathy, in which pathogenetic reactive oxygen intermediates are responsible. However, the mechanism(s) of PGE1 in reducing tissue damage is still unclear. Adult T-cell leukemia-derived factor/human thioredoxin (ADF) is induced by oxidative stresses and has protective activity against oxidative cellular injury. To evaluate the possible involvement of ADF in the tissue-protective effect of PGE1, we analyzed ADF expression immunohistochemically using a rat transient retinal ischemia model. Rats were treated orally with 300 micrograms/kg/day OP-1206 alpha-cyclodextrin clathrate (OP-1206), a stable PGE1 analogue, for 14 days after photodynamic retinal vascular thrombosis by rose Bengal. Rats without any OP-1206 treatment were used as controls. In the OP-1206-treated rats, minimal retinal atrophy due to ischemia/reperfusion was observed histologically up to 14 days, whereas in the non-treated rats the inner layer of the retina became markedly atrophic. In parallel with the histological change, after 14 days following thrombosis ADF immunoreactivity was preserved on retinal pigment epithelial cells in the OP-1206-treated rats, whereas it was diminished in the non-treated rats. These findings suggest an important role for ADF in the OP-1206-dependent suppression of retinal tissue damage caused by oxidative insult.
Yamamoto
M
M
Department of Ophthalmology, Faculty of Medicine, Kyoto University, Japan.
Ohira
A
A
Honda
O
O
Sato
N
N
Furuke
K
K
Yodoi
J
J
Honda
Y
Y
D000527:Alprostadil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D001284:Atrophy; D016207:Cytokines / Q000032:analysis*; D007124:Immunoenzyme Techniques; D008297:Male; D009363:Neoplasm Proteins / Q000032:analysis*; D010857:Pigment Epithelium of Eye / Q000737:chemistry / Q000648:ultrastructure; D011459:Prostaglandins E, Synthetic / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D012160:Retina / Q000737:chemistry* / Q000648:ultrastructure; D012170:Retinal Vein Occlusion / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D013879:Thioredoxins / Q000032:analysis
D016207:Cytokines; D009363:Neoplasm Proteins; D011459:Prostaglandins E, Synthetic; C055533:adult T cell leukemia-derived factor; D013879:Thioredoxins; C025090:ONO 1206; D000527:Alprostadil